Promising Findings Presented at the American College of Neuropsychopharmacology Annual Meeting
, /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”) the market leader in cannabidiol (CBD) hemp extract wellness products, is pleased to share an update on the progress of DeFloria LLC’s (“DeFloria”) botanical pharmaceutical development, an entity established by AJNA BioSciences and Charlotte’s Web. Promising findings from DeFloria’s Phase 1 clinical trial results for AJA001 were presented by Dr. Marcel Bonn-Miller at the American College of Neuropsychopharmacology Annual Meeting on December 11, 2024. AJA001 is being developed for the treatment of symptoms of autism spectrum disorder (ASD).
About AJA001 Oral Solution
AJA001 Oral Solution is being developed by DeFloria as an innovative new botanical drug containing a multi-compound hemp extract with a full spectrum of cannabinoids, bridging the gap between natural wellness products and FDA-regulated medicines that are generally single-compound drugs. Leveraging a proprietary hemp cultivar patented by Charlotte’s Web, the Phase 1 trial, designed …